Niacin AIM HIGH study: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==AIM HIGH study== | ==AIM HIGH study== | ||
* National Heart, Lung and Blood Institute (NHLBI) funded study. | * '''Funding''' - National Heart, Lung and Blood Institute (NHLBI) funded study. | ||
* Hypothesis - | * '''Hypothesis''' - Raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels. | ||
* Early termination of the study as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol and non-HDL-cholesterol. | * '''Results''' - Early termination of the study as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol and non-HDL-cholesterol. | ||
==References== | ==References== | ||
Revision as of 15:00, 20 November 2011
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
AIM HIGH study
- Funding - National Heart, Lung and Blood Institute (NHLBI) funded study.
- Hypothesis - Raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels.
- Results - Early termination of the study as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol and non-HDL-cholesterol.